Humana Inc. HUM
- Market cap
- $45.7B
- P/E
- 37.4×
Follow HUM
Humana Inc. (HUM) EV/Sales
As of 25 September 2026, Humana Inc. (HUM) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from 0.1× (March 2026) to 0.7× (November 2018); the current reading is higher than 17% of that period. That is below the Healthcare Plans industry median of 0.4× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.2× | (0.81%) |
| FY2024 | 0.2× | (59.31%) |
| FY2023 | 0.5× | (23.53%) |
| FY2022 | 0.6× | (10.80%) |
| FY2021 | 0.7× | 18.27% |
| FY2020 | 0.6× | (7.67%) |
| FY2019 | 0.6× | 5.44% |
| FY2018 | 0.6× | 12.94% |
| FY2017 | 0.5× | 26.46% |
| FY2016 | 0.4× | 5.58% |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | 177.98% |
| Mar 2026 | 0.1× | (49.00%) |
| Dec 2025 | 0.2× | 4.18% |
| Sep 2025 | 0.2× | 4.06% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CNC Centene Corporation compare | 0.1× |
| MOH Molina Healthcare, Inc compare | 0.1× |
| HUM Humana Inc. | 0.3× |
| CI Cigna Group compare | 0.3× |
| OSCR Oscar Health, Inc. compare | 0.3× |
| CVS CVS Health Corporation compare | 0.4× |
| ELV Elevance Health, Inc. compare | 0.4× |
| UNH UnitedHealth Group Incorporated compare | 0.8× |
| CLOV Clover Health Investments, Corp. compare | 0.9× |
| Healthcare Plans industry median | 0.4× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on HUM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement